214 related articles for article (PubMed ID: 32161100)
21. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
[TBL] [Abstract][Full Text] [Related]
22. PARP Activity Fine-tunes the DNA Replication Choreography of Chk1-depleted Cells.
Calzetta NL; González Besteiro MA; Gottifredi V
J Mol Biol; 2021 May; 433(10):166949. PubMed ID: 33744317
[TBL] [Abstract][Full Text] [Related]
23. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro.
Li J; Wang J; Yu J; Zhao Y; Dong Y; Fan Y; Li N; Zhang Y; Wang Y
Oncol Rep; 2018 Nov; 40(5):2477-2486. PubMed ID: 30132567
[TBL] [Abstract][Full Text] [Related]
25. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
[TBL] [Abstract][Full Text] [Related]
27. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.
Grabauskiene S; Bergeron EJ; Chen G; Chang AC; Lin J; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
Lung Cancer; 2013 Dec; 82(3):477-84. PubMed ID: 24113549
[TBL] [Abstract][Full Text] [Related]
28. Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.
Mani C; Pai S; Papke CM; Palle K; Gmeiner WH
Neoplasia; 2018 Dec; 20(12):1236-1245. PubMed ID: 30439567
[TBL] [Abstract][Full Text] [Related]
29. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
[TBL] [Abstract][Full Text] [Related]
31. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
32. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
33. Kinesin light chain 4 as a new target for lung cancer chemoresistance via targeted inhibition of checkpoint kinases in the DNA repair network.
Baek JH; Yun HS; Kim JY; Lee J; Lee YJ; Lee CW; Song JY; Ahn J; Park JK; Kim JS; Lee KH; Kim EH; Hwang SG
Cell Death Dis; 2020 May; 11(5):398. PubMed ID: 32457423
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
35. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
[TBL] [Abstract][Full Text] [Related]
36. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
37. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.
Wang Z; Førsund MS; Trope CG; Nesland JM; Holm R; Slipicevic A
Cancer Med; 2018 Aug; 7(8):3955-3964. PubMed ID: 29963769
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
40. Replication stress activates DNA polymerase alpha-associated Chk1.
Taricani L; Shanahan F; Parry D
Cell Cycle; 2009 Feb; 8(3):482-9. PubMed ID: 19177015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
